Probiotics: Definition, Types, and Mechanisms of Action

Definition

• Yamada's Textbook of Gastroenterology, 7th ed.
• Medical Microbiology, 9th ed.

Common Types and Strains

Mechanisms of Action

1. Competitive Exclusion and Colonization Resistance

2. Production of Antimicrobial Substances

• Lactic acid and acetic acid - lower luminal pH, inhibiting growth of harmful bacteria
• Bacteriocins - protein-based antibiotics produced by probiotic organisms that directly kill competing pathogens
• Short-chain fatty acids (SCFAs) - especially butyrate, propionate, and acetate - produced by bacterial fermentation of dietary fiber; SCFAs nourish colonocytes, regulate immune tone, and influence insulin sensitivity in peripheral tissues via SCFA receptors

3. Enhancement of Mucosal Barrier Function

• Upregulate tight junction proteins (e.g., occludin, claudins), reducing gut permeability ("leaky gut")
• Stimulate mucin production, thickening the protective mucus layer
• Promote epithelial cell survival

4. Immunomodulation

• Promote differentiation of T-regulatory (Treg) cells
• Upregulate anti-inflammatory cytokines: IL-10 and TGF-β
• Downregulate pro-inflammatory cytokines: TNF-α and IL-12
• B. infantis in IBS patients has been shown to restore the IL-10:IL-12 ratio from a pro-inflammatory to a normal state
• Interact with dendritic cells and macrophages via pattern-recognition receptors (PRRs), shaping adaptive immune responses

5. Microbiota Composition and Diversity

• Increasing abundance of beneficial anaerobes
• Reducing populations of pathobionts
• Restoring diversity after antibiotic disruption

6. Modulation of the Gut-Brain Axis

• Regulate endocrine signaling (e.g., serotonin production via enterochromaffin cells)
• Influence the vagus nerve
• May reduce visceral hypersensitivity (relevant in IBS and functional gut disorders)

7. Enzymatic and Metabolic Effects

• Modify fecal enzymatic activity involved in metabolism of bile salts
• Inactivate carcinogens and xenobiotics in the gut lumen
• Improve lactose digestion (L. acidophilus, S. thermophilus)
• Enhance bioavailability of vitamins B, C, and K

Key Characteristics That Determine Efficacy

1. Species and strain specificity - effects are strain-specific, not class-wide
2. Dose - measured in colony-forming units (CFU); B. infantis efficacy was seen at 10^8 but not 10^10 CFU in some IBS trials
3. Viability - organisms must be alive at time of ingestion
4. Formulation - acid stability, encapsulation, and shelf storage affect survival through the stomach

Food vs. Supplement Sources

Safety Considerations

• Immunocompromised patients face a small risk of bacteremia/fungemia
• Critically ill patients - probiotics should be avoided, particularly in severe acute pancreatitis. A major Dutch RCT (PROPATRIA trial) found a 16% vs. 6% mortality in probiotic vs. placebo groups, with bowel ischemia as the likely mechanism (Yamada's Textbook of Gastroenterology)
• Many commercial probiotics lack clinical evidence for specific conditions; the species, mixture, dose, and viability all influence therapeutic potential

Recent Evidence (PubMed, 2023-2025)

Probiotics vs. Prebiotics vs. Synbiotics

Side-by-Side Comparison

Probiotics - The Living Agents

• Must be viable at time of ingestion
• Effects are strain-specific - you cannot generalize across all Lactobacillus spp., for example
• Active mechanisms: SCFA secretion, tight junction upregulation, IL-10/TGF-β induction, mucin production, pathogen competitive exclusion
• DNA in probiotic organisms has also been shown to inhibit apoptosis in epithelial cells
• Yamada's Textbook of Gastroenterology, 7th ed.

Prebiotics - The Fuel

• Oligofructose (short-chain) - fermented rapidly in the proximal colon; good dose is ~3.5 g/day for symptom relief, 10 g/day to maximize bifidobacterial growth
• Inulin (long-chain) - fermented more slowly, targeting the distal colon
• Oligofructose-enriched inulin - "full-spectrum" prebiotic targeting the entire colon
• Trans-galactooligosaccharides (trans-GOS) - shown to significantly increase fecal bifidobacteria
• Short-chain fructooligosaccharides (scFOS) - 10 g/day optimal dose in healthy volunteers
• Others with possible prebiotic activity: lactulose, mannitol, xylitol (sugar alcohols)

1. Pass through the small intestine undigested
2. Reach the colon where anaerobic bacteria ferment them
3. Fermentation produces short-chain fatty acids (butyrate, propionate, acetate) - major fuel for colonocytes
4. Selectively increase abundance of Bifidobacterium and Lactobacillus
5. Modulate the immune system by activating carbohydrate receptor immune cells
6. Lower colonic pH, creating an environment hostile to pathogens

• Yamada's Textbook of Gastroenterology, 7th ed.; Fischer's Mastery of Surgery, 8th ed.

Synbiotics - The Combination

"A nondigestible compound that contains both prebiotics and probiotics and combines nutrients appropriate to stimulate the specific beneficial microbe in the synbiotic."

• Complementary synbiotics: the prebiotic and probiotic have independent, additive effects (e.g., B. longum + inulin, where inulin feeds indigenous bifidobacteria regardless of the added strain)
• Synergistic synbiotics: the prebiotic is specifically selected to feed the co-administered probiotic strain (maximizing the survival and establishment of that specific organism)

• Sleisenger & Fordtran's GI and Liver Disease

Postbiotics - A Fourth Category

• Dermatology: 2-Volume Set, 5th ed.

Analogy to Clarify the Relationship

• Probiotics = planting new seeds (introducing live beneficial organisms)
• Prebiotics = fertilizer (feeding the plants/bacteria already there and the newly seeded ones)
• Synbiotics = a pre-packaged kit with seeds + the right fertilizer for those seeds
• Postbiotics = the fruit produced by the plants (beneficial metabolites)

Clinical Relevance

• Goldman-Cecil Medicine; Fischer's Mastery of Surgery; Yamada's Textbook of Gastroenterology

Principles of Antibiotics

1. What is an Antibiotic?

2. Bactericidal vs. Bacteriostatic

• The bactericidal/bacteriostatic distinction is not absolute - an agent may be bactericidal against one organism but bacteriostatic against another (e.g., vancomycin is bactericidal for staphylococci but bacteriostatic for enterococci)
• A meta-analysis found no significant difference in clinical cure rate or mortality between bacteriostatic vs. bactericidal agents for most infections
• Bactericidal agents are preferred when: immunocompromised/neutropenic patients, infective endocarditis, bacterial meningitis
• Fishman's Pulmonary Diseases and Disorders; Campbell Walsh Wein Urology

3. Mechanisms of Action - The Five Major Targets

I. Inhibition of Cell Wall Synthesis

• Beta-lactams (penicillins, cephalosporins, carbapenems, aztreonam): Bind to penicillin-binding proteins (PBPs), enzymes that catalyze the final cross-linking step in peptidoglycan assembly. Without cross-linking, the wall weakens and the bacterium lyses under osmotic pressure.
• Vancomycin: Binds directly to the D-alanyl-D-alanine terminal residues of peptidoglycan precursors, physically blocking transpeptidation. Does not bind PBPs.
• Bacitracin: Inhibits recycling of the lipid carrier (bactoprenol) that transports peptidoglycan subunits across the cell membrane.

II. Inhibition of Protein Synthesis

III. Inhibition of Nucleic Acid Synthesis

• Fluoroquinolones (ciprofloxacin, levofloxacin): Inhibit bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, which are required to relieve DNA supercoiling during replication. Human topoisomerase II has a different structure and is not targeted at therapeutic concentrations. Bactericidal - concentration-dependent killing.
• Rifampin: Inhibits bacterial RNA polymerase (DNA-dependent), blocking transcription. Human RNA polymerase is not susceptible at therapeutic doses.
• Metronidazole: A prodrug activated by anaerobic/microaerophilic organisms; the active metabolite causes DNA strand breaks. Bactericidal.

IV. Disruption of Cell Membrane Integrity

• Polymyxins / Colistin: Cationic lipopeptides that displace membrane cations (Mg²⁺, Ca²⁺), destabilize the outer membrane of gram-negative bacteria, and increase permeability → cell contents leak out → bactericidal. Reserved for multidrug-resistant gram-negative organisms.
• Daptomycin: Cyclic lipopeptide that inserts into the bacterial membrane in a Ca²⁺-dependent manner, causing depolarization and loss of membrane potential → bactericidal. Active against gram-positive organisms only (inactivated by lung surfactant - cannot use for pneumonia).

V. Inhibition of Metabolic Pathways (Antimetabolites)

• Sulfonamides: Structural analogs of para-aminobenzoic acid (PABA), competitively inhibit dihydropteroate synthase → block folate synthesis → bacteriostatic.
• Trimethoprim: Inhibits dihydrofolate reductase (DHFR), the next enzyme in the same pathway. Selective for bacterial DHFR (1000x higher affinity than human DHFR).
• Trimethoprim-sulfamethoxazole (TMP-SMX): Sequential blockade of the same pathway at two steps → synergistic bactericidal effect.

4. Spectrum of Activity

5. Key Pharmacokinetic-Pharmacodynamic (PK/PD) Principles

Time-Dependent Killing (fT > MIC)

• Killing depends on how long the free drug concentration stays above the MIC
• Rate of killing plateaus once concentration exceeds ~4× MIC
• Strategy: Frequent dosing or continuous infusion
• Examples: Beta-lactams (penicillins need fT>MIC for 40-50% of interval; cephalosporins 60-70%), carbapenems, macrolides, linezolid

Concentration-Dependent Killing (Cmax:MIC)

• Killing depends on how high the peak concentration is relative to MIC
• The higher the peak, the more bacteria killed
• Strategy: Infrequent but high doses
• Examples: Aminoglycosides, fluoroquinolones (underlies once-daily aminoglycoside dosing)

AUC-Dependent Killing (AUC:MIC)

• Killing correlates with the total drug exposure over time
• Examples: Vancomycin (target AUC:MIC ≥400 for MRSA), glycopeptides, daptomycin, tigecycline, colistin, and fluoroquinolones (dual category)

Important Concentration Thresholds

Post-Antibiotic Effect (PAE)

• Aminoglycosides and fluoroquinolones: prolonged PAE against gram-negatives (supports once-daily dosing)
• Beta-lactams: minimal/no PAE against gram-negatives (requires continuous time above MIC)
• Fishman's Pulmonary Diseases and Disorders

6. Antibiotic Resistance - Mechanisms

• Campbell Walsh Wein Urology; K.J. Lee's Essential Otolaryngology

7. Summary Diagram

ANTIBIOTICS
│
├── CELL WALL SYNTHESIS INHIBITORS (bactericidal)
│     ├── Beta-lactams → block PBPs
│     ├── Vancomycin → block D-Ala-D-Ala
│     └── Bacitracin → block lipid carrier recycling
│
├── PROTEIN SYNTHESIS INHIBITORS
│     ├── 30S: Aminoglycosides (bactericidal), Tetracyclines (static)
│     └── 50S: Macrolides, Clindamycin, Chloramphenicol, Linezolid (mostly static)
│
├── NUCLEIC ACID SYNTHESIS INHIBITORS
│     ├── Fluoroquinolones → DNA gyrase / topoisomerase IV
│     ├── Rifampin → RNA polymerase
│     └── Metronidazole → DNA strand breaks
│
├── CELL MEMBRANE DISRUPTORS (bactericidal)
│     ├── Polymyxins/Colistin → gram-negative outer membrane
│     └── Daptomycin → gram-positive membrane depolarization
│
└── ANTIMETABOLITES (bacteriostatic)
      ├── Sulfonamides → dihydropteroate synthase
      └── Trimethoprim → dihydrofolate reductase

What Does "Principle" Mean?

In everyday language:

"A principle is a basic idea or rule that underlies something."

• The principle of gravity = the basic rule that mass attracts mass
• A person "with principles" = someone who follows strong moral rules

In science and medicine, "principle" means:

The fundamental mechanism, logic, or rule that a thing operates on.

"What is the basic/fundamental idea behind how antibiotics work?"

"Principle" vs. similar words:

Principles of Antibiotic Therapy

Principle 1 - Confirm That an Infection Exists

• Antibiotics are NOT indicated for viral infections (common cold, flu, most sore throats)
• Fever alone does not mean bacterial infection
• Only spreading infections or signs of systemic infection (fever, raised WBC, hemodynamic changes) justify antibiotic use
• Antibiotics do not replace surgical drainage of abscesses - pus must be drained; antibiotics are an adjunct, not a substitute

"Antibiotics do not replace surgical drainage of infection."

• Bailey & Love's Short Practice of Surgery, 28th ed.

Principle 2 - Identify the Causative Organism Before Starting (Whenever Possible)

• Blood cultures, wound swabs, sputum, urine - taken before antibiotics to maximise yield
• Gram stain provides rapid preliminary guidance (gram-positive vs. gram-negative; cocci vs. rods)
• Formal culture and sensitivity (C&S) testing then follows
• The antibiogram (published annually by each hospital laboratory) summarises local organism-drug susceptibility patterns - essential for empiric choice

• Jawetz, Melnick & Adelberg's Medical Microbiology, 28th ed.

Principle 3 - Choose the Right Drug (Empiric vs. Definitive Therapy)

Empiric Therapy (before culture results)

• Initiated based on the clinical diagnosis and most likely causative organisms for that site/setting
• Uses the "best guess" based on: patient history, site of infection, community vs. hospital-acquired, local resistance patterns (antibiogram), and risk factors for resistant organisms
• Usually broad-spectrum to cover all likely pathogens
• Must be started promptly in severe infection - delay of even 24 hours increases mortality; in septic shock, risk of death rises 7-8% for each hour of delay in the first 6 hours

Definitive (Targeted) Therapy (after culture results)

• Narrow the spectrum to the specific organism identified ("de-escalation")
• Use the most narrow-spectrum effective agent - reduces side effects, costs, disruption of normal flora, and resistance pressure
• De-escalation is a key pillar of antimicrobial stewardship

"Appropriate = at least one agent active in vitro against the pathogen. Adequate = appropriate agent + correct dose + right route + timely administration + penetration to the infection site."

• Fishman's Pulmonary Diseases and Disorders

1. Spectrum of activity - does it cover the likely/known organism?
2. Site of infection - does the drug penetrate there? (e.g., CNS penetration for meningitis)
3. Host factors - allergies, renal/hepatic function, pregnancy, immunosuppression
4. Local resistance patterns - consult the hospital antibiogram
5. Cost and route of administration

Principle 4 - Use the Correct Dose and Route

• Underdosing leads to treatment failure and promotes resistance
• Overdosing causes toxicity
• Dose must be adjusted for:
  • Renal function (CrCl/eGFR) - most antibiotics are renally cleared
  • Hepatic function - drugs metabolised in the liver (e.g., metronidazole, clindamycin)
  • Body weight - especially aminoglycosides
  • Age - pediatric and geriatric dosing differ

• IV - for severe/life-threatening infections, poor oral absorption, or unconscious patients
• Oral - adequate for mild-moderate infections with good bioavailability; IV-to-oral switch ("step-down") should be done as soon as clinical improvement occurs
• Topical - for localised superficial infections

Principle 5 - Use the Correct Duration

• Too short = treatment failure and relapse
• Too long = increased toxicity, cost, disruption of microbiome, and resistance selection
• Duration depends on: site of infection, organism, severity, patient immune status

Principle 6 - Monotherapy vs. Combination Therapy

Use a single agent when possible

"It is therapeutically advisable to treat patients with a single agent that is most specific to the infecting microorganism. This strategy reduces superinfections, decreases emergence of resistant organisms, and minimises toxicity."

• Lippincott's Illustrated Reviews: Pharmacology

Combinations are justified when:

1. Unknown organism / broad empiric coverage needed (e.g., perforated bowel - aerobic + anaerobic coverage)
2. Synergy is required - beta-lactam + aminoglycoside for enterococcal endocarditis
3. Prevention of resistance - TB treatment uses 4-drug regimens (HRZE) to prevent single-gene mutation resistance
4. Polymicrobial infection - abdominal sepsis, diabetic foot infection
5. Severely ill patients where broadened initial coverage is safer than narrowing too early

Disadvantages of combinations:

• Antagonism: a bacteriostatic drug (e.g., tetracycline) can interfere with a bactericidal drug (e.g., penicillin) by halting bacterial growth, making the bactericidal drug ineffective
• Increased toxicity
• Increased cost
• Greater selection pressure for resistance
• Lippincott's Illustrated Reviews: Pharmacology

Principle 7 - Bactericidal vs. Bacteriostatic - Choose Appropriately

Principle 8 - Monitor the Response and Review Regularly

• Is the patient improving clinically?
• Are culture/sensitivity results available? If yes → de-escalate
• Is the current drug appropriate, or does resistance suggest a change?
• Are there signs of adverse effects (nephrotoxicity with aminoglycosides/vancomycin, hepatotoxicity, CDI)?

• Aminoglycosides (peak and trough levels; once-daily dosing to maximise Cmax:MIC and minimise nephrotoxicity)
• Vancomycin (AUC:MIC monitoring; target AUC:MIC ≥400 for MRSA)

• Wrong organism/drug selection
• Undrainable collection of pus (surgical issue)
• Resistant organism emerging
• Superinfection (C. difficile, fungal)
• Non-infectious cause of fever

Principle 9 - Prevent Adverse Effects and Superinfection

Adverse effects to watch for:

Superinfection

• Clostridioides difficile colitis (pseudomembranous colitis)
• Oral/vaginal candidiasis
• MRSA, VRE, Pseudomonas in hospital settings

Principle 10 - Antimicrobial Stewardship (AMS)

"Optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to patients and minimal impact on subsequent resistance."

• IDSA/SHEA Guidelines

1. Right drug - based on likely/confirmed organism and local antibiogram
2. Right dose - adjusted for patient weight, renal/hepatic function
3. Right route - IV only when necessary; switch to oral early
4. Right duration - shortest course that achieves cure
5. Right patient - only when a true bacterial infection is confirmed

• Use narrow-spectrum over broad-spectrum whenever possible
• De-escalate from broad to narrow empiric therapy as soon as cultures are available
• Rotate antibiotics in units with endemic resistant organisms (e.g., Pseudomonas, Klebsiella)
• Avoid antibiotics for viral infections entirely
• Use prophylactic antibiotics only for defined indications (surgical prophylaxis = single pre-op dose)
• Bailey & Love's Surgery; Fishman's Pulmonary Diseases and Disorders; IDSA/SHEA Guidelines

Summary